Arzerra

Active Ingredient(s): Ofatumumab
FDA Approved: * October 26, 2009
Pharm Company: * GLAXO GRP LTD
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Arzerra Overview

Ofatumumab[1] (trade name Arzerra, also known as HuMax-CD20) is a fully human monoclonal antibody (for the CD20 protein) which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating follicular lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis. Ofatumumab has al...

Read more Arzerra Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ofatumumab

Recent Arzerra Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ofatumumab
  • Injection: 100mg/5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Arzerra: (4 results)

Sorted by National Drug Code
  • 0078-0669 Arzerra 20 mg/ml Intravenous Injection, Solution by Novartis Pharmaceuticals Corporation
  • 0078-0690 Arzerra 20 mg/ml Intravenous Injection, Solution by Novartis Pharmaceuticals Corporation
  • 0173-0821 Arzerra 20 mg/ml Intravenous Injection, Solution by Glaxosmithkline LLC
  • 63379-023 Arzerra 20 mg/ml Intravenous Injection, Solution by Glaxo Operations Uk Ltd

Other drugs which contain Ofatumumab or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 12 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA